Incidence, Risk Factors for and Outcomes of Transplant‐Associated Thrombotic Microangiopathy. (2nd March 2020)

• Record Type: Journal Article
• Authors: Epperla, Narendranath; Li, Ang; Logan, Brent; Fretham, Caitrin; Chhabra, Saurabh; Aljurf, Mahmoud; Chee, Lynette; Copelan, Edward; Freytes, César O.; Hematti, Peiman; Lazarus, Hillard M.; Litzow, Mark; Nishihori, Taiga; Olsson, Richard F.; Prestidge, Tim; Saber, Wael; Wirk, Baldeep; Yared, Jean A.; Loren, Alison; Pasquini, Marcelo
• Other Names: Abraham Allistair A. investigator.; Agrawal Vaibhav investigator.; Aljurf Mahmoud investigator.; Askar Medhat investigator.; Barba Pere investigator.; Bertaina Alice investigator.; Cahn Jean‐Yves investigator.; Cerny Jan investigator.; Choe Hannah K. investigator.; Diaz Miguel Angel investigator.; Dvorak Christopher investigator.; Farhadfar Nosha investigator.; Gadalla Shahinaz M. investigator.; Gergis Usama investigator.; Ganguly Siddhartha investigator.; Hashmi Shahrukh investigator.; Kasow Kimberly A. investigator.; Nathan Sunita investigator.; Nusrat Roomi investigator.; Seo Sachiko investigator.; Shah Niketa C. investigator.
• Is Part Of: British journal of haematology. Volume 189:Number 6(2020)
• Page Start: 1171
• Page End: 1181
• Publication Date: 2020-03-02
• Subjects: thrombotic microangiopathy -- TA‐TMA -- allogeneic transplantation -- allo‐HCT; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16457
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Transplant‐associated thrombotic microangiopathy (TA‐TMA) is a complication of allogeneic transplantation (allo‐HCT). The incidence and risk factors associated with TA‐TMA are not well known. A retrospective analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR) was conducted including patients receiving allo‐HCT between 2008 and 2016, with the primary objective of evaluating the incidence of TA‐TMA. Secondary objectives included identification of risk factors associated with TA‐TMA, and the impact of TA‐TMA on overall survival and the need for renal replacement therapy (RRT). Among 23, 665 allo‐HCT recipients, the 3‐year cumulative incidence of TA‐TMA was 3%. Variables independently‐associated with increased incidence of TA‐TMA included female sex, prior autologous transplant, primary disease (acute lymphoblastic leukaemia and severe aplastic anaemia), donor type (mismatched or unrelated donor), conditioning intensity (myeloablative), GVHD prophylaxis (sirolimus + calcineurin inhibitor), pre‐transplant kidney dysfunction and acute GVHD (time‐varying effect). TA‐TMA was associated with higher mortality (HR = 3·1, 95% Confidence Interval [CI] = 2·8–16·3) and RRT requirement (HR = 7·1, 95% CI = 5·7–311·6). This study provides epidemiologic data on TA‐TMA and its impact on transplant outcomes. Increased awareness of the risk factors will enable providers to be vigilant of this uncommon but serious transplant complication. The results will also provide benchmarking for future study designs and comparisons.